Boston, MA 06\/09\/2014 (wallstreetpr) \u2013 Baxter International Inc. (NYSE:BAX)<\/b> progresses in the terms of safety by curtailing the amount of uremic toxins that are associated with the conventional VIVIA Haemodialysis. The above was concluded only after adequate results from two major studies were collected and proved to be supporting the analysis. In Europe, December 2013; the HD system was developed and gained market approval in order to provide high dosage even at home.<\/p>\n
Important Dates<\/b><\/p>\n
The 51st congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA) marked the announcement of the supporting data that were pertaining to the safety and advancement of the VIVIA HD system to the European nephrology community. This global strategy conference was held to introduce its efficient and effective HD system was held at Amsterdam between May 31 and June 3, 2014.<\/p>\n
A Word From The Company’s M.D.<\/b><\/p>\n
Mr. Bruce Culleton, M.D. of Baxter International Inc. (NYSE:BAX) proclaimed in favor of the current research and said that this patient friendly design in the new research will prove useful in increasing the number of patients being treated and grant them the access to High Dose HD treatment even at the home environment.<\/p>\n
Brief Insight On The Study<\/b><\/p>\n
VIVIA technology enabled the multiple uses of the same dialyzer on the same patient which increased the feasibility and dialysis adequacy. The haemodialysis centre in United States is where the first study was conducted. Four HD treatments were provided to 22 patients with average dialysis duration of 3.8 hours per treatment. In the second undertaking, haemodialysis centre of Canada, 17 patients had undergone the therapy with a frequency of three times per week for a span of 7 hours each. During each instance of the study, no serious device related technical issues were reported.<\/p>\n
Key Point<\/b><\/p>\n
The data, when scrutinized, revealed that this new haemodialysis technology also showed abundant signs of cutting down the emissions when compared to the conventional system. This makes the device convenient for in-house use because of its tendency to emit low carbon footprint and multiple usages of the same dialyzer and blood set.<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 06\/09\/2014 (wallstreetpr) \u2013 Baxter International Inc. (NYSE:BAX) progresses in the terms of safety by curtailing the amount of uremic toxins that are associated […]<\/p>\n","protected":false},"author":2,"featured_media":24748,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[3855,3853,3854],"stock_ticker":[],"class_list":["post-25044","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-baxter-international-inc","tag-baxter-international-inc-nysebax","tag-nysebax","entry"],"acf":[],"yoast_head":"\n